Outcome of Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Post-Immune Checkpoint Inhibitor (ICI) Treatment

被引：0
|
作者：
Park, J. C. [1 ,2 ]
Merkin, R. D. [1 ,2 ]
Wirth, L. [1 ,2 ]
Patel, M. J. [1 ,2 ]
Roberts, T. J. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
158
引用
收藏
页码：E41 / E41
页数：1
相关论文
共 50 条
  • [1] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [2] Weekly Paclitaxel, Carboplatin, and Cetuximab (PCC) as Treatment for Recurrent or Metastatic Head and Neck Squamous-cell Carcinoma (RM-HNSCC) that Progressed on Immune Checkpoint Inhibitors (ICI): A Retrospective Analysis
    Bonomi, M.
    Abu-Sbeih, H.
    Klamer, B.
    Issa, M.
    Rind, F.
    Dibs, K.
    Konieczkowski, D. J.
    Gogineni, E.
    Pan, J.
    Old, M.
    Tili, E.
    Chakravarti, A.
    Grecula, J. C.
    Baliga, S.
    Carrau, R.
    Rocco, J. W.
    Blakaj, D. M.
    Bhateja, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E41 - E42
  • [3] The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort
    Lynggaard, Charlotte Duch
    Therkildsen, Marianne Hamilton
    Kristensen, Claus Andrup
    Specht, Lena
    ACTA ONCOLOGICA, 2015, 54 (07) : 1071 - U151
  • [4] Artificial intelligence (AI)-powered spatial tumor-infiltrating lymphocyte (TIL) analysis in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitor (ICI) treatment
    Hong, M.
    Kim, C. G.
    Hong, M. H.
    Koh, Y. W.
    Hong, H. J.
    Kim, D.
    Sim, N. S.
    Lee, C. G.
    Kim, K. H.
    Kim, S.
    Oum, C.
    Lim, Y.
    Song, S.
    Ock, C. Y.
    Yoon, S. O.
    Kim, H. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S564 - S564
  • [5] Nutritional needs in patients with recurrent/metastatic Head & Neck Cancer (R/M HNSCC) receiving immune checkpoint inhibitors (ICI)
    Brown, Teresa
    Camilleri, Belinda
    Bauer, Judy
    Nottage, Michelle
    Hughes, Brett G. M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 125 - 126
  • [6] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
    Economopoulou, Panagiota
    Gavrielatou, Niki
    Papaxoinis, George
    Kotsantis, Ioannis
    Pantazopoulos, Anastasios
    Anastasiou, Maria
    Kavourakis, George
    Gkolfinopoulos, Stavros
    Psyrri, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [10] Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
    Rotllan, N. Baste
    Auperin, A.
    Iacob, M.
    Sampetrean, A.
    Bouguetta, D.
    Badis, L. Mayache
    Ferrand, F. R.
    Casiraghi, O.
    Blanchard, P.
    Bidault, F.
    Gorphe, P.
    Temam, S.
    Champiat, S.
    Even, C.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 470 - 470
12345